Fusion Pharmaceuticals

At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. As we are a spin-out of a leading manufacturer and distributor of radiopharmaceuticals, the Centre for Probe Development and Commercialization (CPDC), we have experience building a robust supply chain. At Fusion, we develop targeted alpha therapeutics with the forethought of scale-up and reliable commercial production to meet the needs of the global market. We believe our proprietary Fast-Clear™ linker technology is a safer approach to targeted radiopharmaceuticals. Fast-Clear™ represents a revolutionary step towards developing safe and effective new radiotherapeutics as the standard of care for the treatment of multiple tumor types. We believe this evolution of radiopharmaceuticals holds great promise to improve the lives of patients with cancer. Our team is dedicated to improving the lives of cancer patients and positively impacting patients’ families and the community.